Found: 8
Select item for more details and to access through your institution.
Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
- Published in:
- Allergy & Asthma Proceedings, 2021, v. 42, n. 4, p. 274, doi. 10.2500/aap.2021.42.210034
- By:
- Publication type:
- Article
Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening.
- Published in:
- Allergy & Asthma Proceedings, 2020, v. 41, p. S22, doi. 10.2500/aap.2020.41.200062
- By:
- Publication type:
- Article
Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1829, doi. 10.1007/s13555-021-00593-x
- By:
- Publication type:
- Article
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks.
- Published in:
- Allergy, Asthma & Clinical Immunology, 2019, v. 15, n. 1, p. N.PAG, doi. 10.1186/s13223-019-0328-3
- By:
- Publication type:
- Article
Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
- Published in:
- Pediatric Allergy, Immunology & Pulmonology, 2020, v. 33, n. 3, p. 136, doi. 10.1089/ped.2020.1143
- By:
- Publication type:
- Article
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
- Published in:
- Allergy, 2024, v. 79, n. 3, p. 724, doi. 10.1111/all.15948
- By:
- Publication type:
- Article